Skip to main content
TipRanks
Go Ultimate75% OFF

Pacific Edge Limited (PEB) AI Stock Analysis

2 Followers
NZ:PEB

Pacific Edge Limited

(NZX:PEB)

Select Model
Rating:42Neutral
Price Target:NZD 0.25â–¼(-0.39% Downside)
Action:initiatedcoverage
Date:10/05/26

The score is primarily held down by very weak financial performance—sharp FY2026 revenue contraction, negative gross profit, and ongoing cash burn alongside significant equity erosion. Technicals are also soft with weak momentum and the price below key short- to mid-term moving averages, offering only limited signs of stabilization. Valuation is constrained by losses (negative P/E) and no indicated dividend support.

Positive Factors
Low LeverageLow leverage reduces refinancing pressure and preserves more flexibility than a heavily debt-funded balance sheet. This gives Pacific Edge greater room to manage operating volatility and potentially redirect capital toward its diagnostic platform, despite the company’s broader financial challenges.
Negative Factors
Revenue ContractionThe sharp FY2026 revenue decline signals weakening commercial momentum and reduces the scale over which Pacific Edge can spread its operating costs. Persistent contraction would limit investment capacity, weaken market development efforts, and make a return to sustainable profitability more difficult.

Pacific Edge Limited (PEB) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%NZ:PEB+53.61%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 167.59M
Dividend Yield
―
Average Volume (3M)
757.48K
Price to Earnings (P/E)
-6.7
Beta (1Y)
-1.19
Revenue Growth
-47.36%
EPS Growth
-3.79%
Country
NZ
Employees
114
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Pacific Edge Limited Business Overview & Revenue Model

Company Description

Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at...

Pacific Edge Limited Earnings Call Summary

Earnings Call Date:Nov 25, 2025(Q2-2026)|% Change Since:53.61%|Next Earnings Date:Nov 23, 2026
Earnings Call SentimentNeutral

The earnings call presents a mixed view, with notable strategic achievements and promising future prospects, particularly with the upcoming Contractor Advisory Committee. However, significant challenges remain due to reduced revenue, test volumes, and the impact of Medicare non-coverage, creating financial strains and operational hurdles.

Positive Updates

Strategic Positioning and Market Presence
Despite a net loss, Pacific Edge maintains a strong strategic position by achieving significant milestones and maintaining a U.S. market presence to appeal Medicare and commercial tests. The company is in the strongest position to drive Medicare policy change.

Negative Updates

Decline in Operating Revenue
Operating revenue was down to $5.9 million from $10.9 million in the previous half, mainly due to the loss of Medicare coverage.

Company Guidance

In the Pacific Edge 1H Financial Results Presentation for Fiscal Year 2026, the company reported a net loss of $19.1 million and operating revenue of $5.9 million, down from $10.9 million in the previous period. Cash reserves were at $22.1 million, partly bolstered by a $20.7 million capital raise in August 2025. The company faced challenges due to a Medicare non-coverage determination, impacting test volumes and revenue, especially in the U.S. However, Pacific Edge achieved a milestone with Triage Plus, securing a price of USD 1,328 per test, up from $760. Sales force efficiency was maintained, with a sales FTE average of 12, down from over 30, reflecting cost management efforts. The company is optimistic about a potential Medicare re-coverage following a Contractor Advisory Committee (CAC) meeting scheduled for February 19, 2026. They are appealing over 2,000 denied tests to Medicare and commercial providers, expecting revenue recognition in the second half of the year. Additionally, Pacific Edge is pursuing international market expansion with IVD products and focusing on product innovation like Triage Plus and Surveillance Plus for long-term growth.

Pacific Edge Limited Financial Statement Overview

Summary

Overall fundamentals are very weak: sustained operating losses and deeply negative net margins, with FY2026 revenue down ~32% YoY and gross profit turning negative. Cash flow remains materially negative (FY2026 operating cash flow about -31.9M; free cash flow about -32.1M), indicating ongoing cash burn. A partial offset is low leverage, but equity has eroded sharply (about 116.6M in FY2022 to ~10.7M in FY2026), reducing financial flexibility if losses persist.

Income Statement

18Very Negative

Balance Sheet

46Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue11.50M11.50M21.85M26.06M19.62M11.45M
Gross Profit-107.00K-936.00K8.44M14.31M9.60M4.56M
EBITDA-34.94M-35.23M-31.35M―-32.80M-21.80M
Net Income-35.78M-35.78M-29.94M-29.54M-26.96M-19.79M
Balance Sheet
Total Assets17.60M17.60M37.03M65.45M97.12M124.03M
Cash, Cash Equivalents and Short-Term Investments7.78M7.78M22.57M50.26M77.79M105.41M
Total Debt1.28M1.28M2.90M4.21M1.22M1.92M
Total Liabilities6.94M6.94M10.95M10.83M8.71M7.43M
Stockholders Equity10.66M10.66M26.09M54.62M88.41M116.60M
Cash Flow
Free Cash Flow-32.05M-32.07M-26.01M-27.12M-28.48M-18.68M
Operating Cash Flow-31.94M-31.94M-24.74M-25.75M-25.57M-17.55M
Investing Cash Flow12.95M12.95M6.70M22.19M22.47M-52.13M
Financing Cash Flow17.48M17.48M-1.64M-1.11M-1.28M100.66M

Pacific Edge Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.26

Price Trends

50DMA0.25Positive
100DMA0.26Negative
200DMA0.24Positive

Market Momentum

MACD0.01Negative
RSI48.79Neutral
STOCH32.69Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:PEB, the sentiment is Neutral. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.25, and above the 200-day MA of 0.24, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 48.79 is Neutral, neither overbought nor oversold. The STOCH value of 32.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NZ:PEB.

Pacific Edge Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:PEB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:FPHNZ:FPH80OutperformNZD 29.03B61.6122.84%1.24%15.59%23.94%
NZ:EBONZ:EBO56NeutralNZD 4.54B16.717.99%5.69%16.36%5.52%
NZ:AFTNZ:AFT54NeutralNZD 485.57M32.4614.07%0.64%22.44%23.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:PEBNZ:PEB42NeutralNZD 341.52M-6.66-190.54%―-47.36%-3.79%
NZ:TRUNZ:TRU37UnderperformNZD 8.38M-2.58-75.57%―42.20%23.68%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%NZ:PEBNZ:EBONZ:FPHNZ:TRUNZ:AFTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:PEB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:PEBPacific Edge Limited0.260.0740.88%
NZ:EBOEBOS Group Limited21.65-5.75-20.98%
NZ:FPHFisher & Paykel Healthcare Corporation Limited49.2912.5734.25%
NZ:TRUTruScreen Group Ltd.0.01-0.01-41.18%
NZ:AFTAFT Pharmaceuticals Ltd.4.590.9325.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026